Almirall seeks partnership
This article was originally published in Scrip
The Spanish pharmaceutical company Almirall is aiming to strike a deal for the development and commercialisation of its long-acting beta agonist, LAS100977. The new, unnamed chemical entity could be a step forward in the treatment of asthma and chronic obstructive pulmonary disease, the company says.
You may also be interested in...
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.